Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04783181
Recruitment Status : Recruiting
First Posted : March 5, 2021
Last Update Posted : May 13, 2022
Sponsor:
Information provided by (Responsible Party):
Adrenas Therapeutics Inc

Brief Summary:
This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.

Condition or disease Intervention/treatment Phase
Congenital Adrenal Hyperplasia Biological: AAV BBP-631 Phase 1 Phase 2

Detailed Description:
Participants will receive a single dose of intravenous (IV) BBP-631 and are monitored for 52 weeks post-treatment. All participants who receive AAV5 based BBP-631 will be followed for an additional 4 years for safety and efficacy in a separate long-term follow-up study. In total, all participants will be followed for at least 5 years after the date of treatment with BBP-631.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Participants will be assigned sequentially to one of 3 dose levels depending on the date of determination of eligibility.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene
Actual Study Start Date : July 1, 2021
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : December 2024


Arm Intervention/treatment
Experimental: Dose Level 1
BBP-631 lowest dose, administered once, intravenously (IV)
Biological: AAV BBP-631
intravenous

Experimental: Dose Level 2
BBP-631 middle dose, administered once, IV
Biological: AAV BBP-631
intravenous

Experimental: Dose Level 3
BBP-631, highest dose, administered once, IV
Biological: AAV BBP-631
intravenous




Primary Outcome Measures :
  1. Number of participants with Treatment-emergent Adverse Events that Led to Study Discontinuation [ Time Frame: up to 3 years ]
  2. To select the optimum dose or dose range of BBP 631 for future studies [ Time Frame: up to 3 years ]

Secondary Outcome Measures :
  1. Change from Baseline in 17-OHP (hydroxyprogesterone) levels [ Time Frame: Baseline, Week 52 ]
  2. Change from Baseline in endogenous cortisol levels [ Time Frame: Baseline, Week 52 ]
  3. Change from Baseline in androstenedione (A4) levels [ Time Frame: Baseline, Week 52 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  1. Adult male and non-pregnant females with classic CAH (simple virilizing or salt-wasting) due to 21-OHD
  2. Screening/baseline 17-OHP levels > 5-10 × ULN and < 40 × ULN (upper limit of normal)
  3. Stable oral hydrocortisone (HC) regimen as the only glucocorticoid (GC) maintenance therapy
  4. Naïve to prior gene therapy or AAV-mediated therapy

Key Exclusion Criteria

  1. Positive for anti-AAV5 (Adeno-Associated Virus Type 5) antibodies
  2. History of adrenalectomy and has no significant liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04783181


Contacts
Layout table for location contacts
Contact: David Rintell, Ed.D., VP, Head of Patient Advocacy 617-734-6778 ClinicalTrials@AdrenasTx.com
Contact: Mel Pozun

Locations
Layout table for location information
United States, California
Children's Hospital Los Angeles Not yet recruiting
Los Angeles, California, United States, 90027
Contact: Norma Martinez    323-361-5627    nzmartinez@chla.usc.edu   
Principal Investigator: Mimi Kim, MD MSc         
Rady Children's Hospital - San Diego Not yet recruiting
San Diego, California, United States, 92123
Contact: Marla B Hashiguchi, BSN    858-966-8940    mhashiguchi@rchsd.org   
Principal Investigator: Ron Newfield, MD         
United States, Illinois
Ann and Robert H. Lurie Children's Hospital of Chicago Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Sarayu Ratnam    312-227-6617    sratnam@luriechildrens.org   
Contact    312-227-6090      
Principal Investigator: Courtney Finlayson, MD         
United States, Maryland
National Institutes of Health Clinical Center Not yet recruiting
Bethesda, Maryland, United States, 20892-1932
Contact: Office of Patient Recruitment    800-411-1222    prpl@cc.nih.gov   
Contact: Elizabeth Joyal (Study Coordinator), CRNP    301-496-8542    ejoyal@nih.gov   
Principal Investigator: Deborah Merke, M.D., M.S.         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Coordinator Office    612-624-8672    saraf010@umn.edu   
Contact: Coordinator Office    612-626-7024      
Principal Investigator: Kyriakie Sarafoglou, M.D.         
United States, North Carolina
Lucas Research, Inc. Not yet recruiting
Morehead City, North Carolina, United States, 28557
Contact: Crystal Gann, CCRC    252-222-5700 ext 135    crystal.gann@lucasresearch.org   
Principal Investigator: K. Jean Lucas, MD,FACP,FACE         
Sponsors and Collaborators
Adrenas Therapeutics Inc
Additional Information:
Layout table for additonal information
Responsible Party: Adrenas Therapeutics Inc
ClinicalTrials.gov Identifier: NCT04783181    
Other Study ID Numbers: CAH-301
First Posted: March 5, 2021    Key Record Dates
Last Update Posted: May 13, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Adrenas Therapeutics Inc:
CAH
Gene therapy
AAV
AAV5
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenal Hyperplasia, Congenital
Adrenogenital Syndrome
Adrenocortical Hyperfunction
Hyperplasia
Pathologic Processes
Disorders of Sex Development
Urogenital Abnormalities
Congenital Abnormalities
Genetic Diseases, Inborn
Steroid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases
Adrenal Gland Diseases
Endocrine System Diseases
Gonadal Disorders